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Key Points
• Heme and iron induce
macrophage phenotypic
switching toward an M1
proinflammatory phenotype.
• By scavenging free heme,
hemopexin reverts heme-
induced proinflammatory
activation of macrophages in
a mouse model of sickle cell
disease.
Hemolytic diseases, such as sickle cell anemia and thalassemia, are characterized by en-
hanced release of hemoglobin and heme into the circulation, heme-iron loading of reticulo-
endothelial systemmacrophages, and chronic inflammation. Here we show that in addition
toactivating thevascular endothelium,hemoglobinandhemeexcessalters themacrophage
phenotype in sickle cell disease.Wedemonstrate that exposure of culturedmacrophages to
hemolytic aged red blood cells, heme, or iron causes their functional phenotypic change
toward a proinflammatory state. In addition, hemolysis and macrophage heme/iron accu-
mulation in a mouse model of sickle disease trigger similar proinflammatory phenotypic
alterations in hepatic macrophages. On the mechanistic level, this critically depends on
reactive oxygen species production and activation of the Toll-like receptor 4 signaling path-
way. We further demonstrate that the heme scavenger hemopexin protects reticulo-
endothelial macrophages from heme overload in heme-loaded Hx-null mice and reduces
production of cytokines and reactive oxygen species. Importantly, in sickle mice, the ad-
ministration of human exogenous hemopexin attenuates the inflammatory phenotype of
macrophages. Taken together, our data suggest that therapeutic administrationof hemopexin is beneficial to counteract heme-driven
macrophage-mediated inflammation and its pathophysiologic consequences in sickle cell disease. (Blood. 2016;127(4):473-486)
Introduction
Several pathologic states are hallmarked by systemic or local release of
hemoglobin (Hb) and heme from red blood cells. Sickle cell disease
(SCD) and malaria are paradigmatic hemolytic disorders, in which
alteration in the structure of red blood cells (RBCs) leads to the release
of Hb and heme into the circulation.
Heme is a toxic and pro-oxidant molecule when released in
excessive amounts.1-3 To counteract the potentially detrimental effects
of Hb and heme, mammals are equipped with extracellular scavenging
systems, namely haptoglobin (Hp) and hemopexin (Hx), that bind Hb
and heme, respectively.4 Hp-Hb and Hx-heme complexes are taken up
by receptor-mediated endocytosis into macrophages and hepatocytes,
respectively.1,5-9 Reticulo-endothelialmacrophages located in liver and
spleen constitute the major sites for the clearance of aged or damaged
RBCs. Following RBC phagocytosis or Hp-mediated Hb internaliza-
tion, Hb is degraded and heme-iron is recycled for de novo
erythropoiesis.3 Within cells, heme is catabolized by the activity of
heme oxygenases (inducible HO-1 and constitutive HO-2) into iron,
carbon monoxide, and biliverdin. The iron is then either bound by the
iron storage protein ferritin, to prevent iron-mediated generation of
radicals, or exported into the bloodstream by the iron exporter
ferroportin (Fpn).10-12 Both RBC clearance and extracellular Hb
scavenging are relatively modest events under steady-state conditions,
but are drastically enhanced in hemolytic disorders.13,14 High levels
of extracellular Hb and heme ultimately lead to the saturation and
depletion of the Hp/Hx scavenging systems,15 causing heme-mediated
oxidative tissue damage.16
Increasing evidence demonstrates that heme acts as a proinflamma-
torymolecule that binds and activates Toll-like receptor 4 (TLR4), thus
inducing the activation of endothelial cells17 and the production of
inflammatory cytokines, such as tumor necrosis factor (TNF)a in
neutrophils and macrophages.18-22 These observations are interesting
in the context of SCD,23-28 malaria,29,30 and other pathologic conditions
associated with hemoglobin/heme release,15 such as sepsis,31-34
atherosclerosis,35,36 intracerebral hemorrhage,37,38 and infections,39 in
which levels of proinflammatory cytokines are increased. For example,
monocytes from SCD patients show an enhanced state of activation,
with increased expression of interleukin (IL)-15 and production of
TNFa and IL-1b.40
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Reticuloendothelial system macrophages are characterized by
marked phenotypical and functional heterogeneity, depending on the
microenvironment and the cytokine composition of the niche.41-43
A wide variety of macrophage subtypes has been described both in
vitro and in vivo. The 2 extremes are represented by “classically
activated” orM1macrophages,which are induced bymicrobial agents
and proinflammatory T-helper (Th)1 cytokines (interferon-g, lipo-
polysaccharide), and “alternatively activated” or M2 macrophages,
Figure 1. Hx protects macrophages from heme overload. (A-B) Heme content in the spleen and in splenic myeloid cells (CD11b1 granulocytes, monocytes, and ferromagnetic
macrophages) from untreated (NT) and heme-treated (1heme) (hemin 70 mmol/kg; 1 hour after injection) wild-type (Wt) and Hx-null (Hx2/2) mice (n5 3). (C-G) HO-1, L-ferritin, and
FPNmRNA and protein expression in splenic myeloid cells (granulocytes, monocytes, andmacrophages) isolated from the spleen of untreated (NT) or heme-treated (hemin 70 mmol/kg;
6 hours after injection) wild-type and Hx-null mice. In C and F, HO-1 and FPNmRNA levels were analyzed by qRT-PCR (NT: n5 5; heme: n5 6). Representative western blots of HO-1,
L-ferritin, and FPN are shown in D, E, and G (NT: n 5 3; heme: n 5 6). (H) qRT-PCR analysis of IL-6 mRNA expression in splenic myeloid cells isolated from the spleen of untreated
(NT) or heme-treated wild-type and Hx-null mice (hemin 70 mmol/kg; 6 hours after injection) (untreated, NT: n5 3; heme: n5 6). Values represent mean6 SEM. *P, .05; **P, .01;
***P , .001. mRNA levels measured by qRT-PCR are expressed in relative quantity (RQ) to the untreated (NT) sample (RQ 5 1); densitometric analysis is reported in arbitrary units
(AUs), as the ratio to the untreated (NT) sample (AU 5 1).
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Figure 2. Hx limits heme uptake, iron loading, and the production of ROS and cytokines in BMDM and Raw264.7 cells. (A) Heme levels in BMDMs treated with 5 mM
Hx-heme or HSA-heme for 30 minutes (n 5 3). (B) Heme levels in Raw264.7 cells treated with Hx-heme, HSA-heme, MSA-heme, or heme alone for 15, 30, or 60 minutes
(n 5 3). (C-H) HO-1, H- and L-ferritin, and FPN expression in Raw264.7 cells incubated with 5 mM Hx-heme, MSA-heme, or heme alone for the indicated times. In C and G,
HO-1 and FPN mRNAs were analyzed by qRT-PCR (n 5 4). Representative western blots are shown in D, E, F, and H (untreated, NT: n 5 3; heme: n 5 9). (I) Measurement
of ROS levels in Raw264.7 cells treated with 10 mM Hx-heme, HSA-heme, or heme alone (6 and 15 hours; n 5 4). (J-K) qRT-PCR analysis of TNFa and IL-6 mRNA
expression in Raw264.7 cells treated with 5 mM Hx-heme or HSA-heme for 4 hours (n 5 6). Values represent mean 6 SEM. *P , .05; **P , .01; ***P , .001. mRNA levels
measured by qRT-PCR are expressed in RQ to the untreated (NT) sample (RQ 5 1); densitometric analysis is reported in AU, as the ratio to the untreated (NT) sample
(AU 5 1).
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mainly induced by Th2 cytokines (IL-4, IL-10, IL-13).41-45 These
macrophage populations are functionally different: M1 cells have
inflammatory functions andbactericidal activity andproduce high levels
of proinflammatory cytokines and reactive nitrogen and oxygen
radicals; M2 cells have immunoregulatory functions, aid parasite
clearance, show increased phagocytic activity, and are involved in
cell growth control, matrix remodeling, angiogenesis, and tissue repair.
Recent studies suggest that M1 and M2 macrophages show
different expression profiles of iron-related genes.46-49 However, the
questionwhetherHb,heme,or ironcoulddirectlyaffect thephenotypeof
macrophages andwhether heme/iron scavengers could alter or revert this
effect has never been investigated. Despite the fact that the dichotomous
M1/M2 nomenclature often appears as an oversimplification and does
not fully reflect on the complex biology of macrophage subsets, in this
study, we took these phenotypes as a reference and analyzed expression
of established M1 and M2 markers to define whether heme and iron
polarize macrophages toward a pro- or anti-inflammatory phenotype.
We now show that heme, and specifically its iron moiety, promotes
pronounced phenotypic changes inmacrophages toward anM1-like
proinflammatory phenotype, a response mediated by TLR4 signaling
and reactive oxygen species (ROS) production. Importantly, the heme
scavenger Hx prevents heme-induced proinflammatory phenotypic
switching, both in vitro and in vivo. Additionally, administration of
exogenous Hx in an experimental model for hemolysis and a mouse
model of SCD is beneficial to counteract the heme-driven proinflamma-
tory statusofmacrophagesand itspathophysiologicconsequences.These
findings have important implication for the control of the inflammatory
response in patients showing acute or chronic Hb and heme release.50
Materials and methods
Mouse models and treatments
Wild-type, Hx-null,51 TLR4-null52 (on B6J or SV129 genetic background), and
knock-in HbA and HbS sickle mice (on mixed genetic background)53 were
housed in the animal facility of the Molecular Biotechnology Center (Turin) or
Innerbetriebliche Fortbildung (Heidelberg, only for bone marrow–derived
macrophage [BMDM]preparation) andmaintained on a standard diet containing
200 ppm iron (Teklad 2018S; Harlan). Mouse breeding and experiments were
approved by and conducted in compliance with the guidelines of the University
of Heidelberg (Germany) and Turin (Italy).
Cell treatment
Raw264.7 cells and BMDMs were treated with 23 107 hemolytic aged RBCs,
5 to 15 mM heme or Zn-mesoporphyrin bound to 5 to 15 mM albumin or Hx,
or with 100 mM iron-nitrilotriacetate (FeNTA) alone or bound to 100 mM
desferrioxamine (DFO).
Preparation of splenic and hepatic macrophages and flow
cytometry analysis
Splenicandhepaticmacrophage-enriched fractions, obtainedbyspleenmechanical
disruption or liver enzymatic digestion, were analyzed by flow cytometry, as
described in supplemental Data available on the BloodWeb site.
Statistical analysis
Results were expressed as mean 6 standard error of the mean (SEM).
Comparisons between 2 groups were performed with 2-sidedWelch t tests, and
among 3 or .3 groups with 1- or 2-way analyses of variance, respectively,
followed by the Bonferroni posttest. P, .05 was considered significant.
Further details onmaterials andmethods have been included in supplemental
Materials and Methods.
Results
Lack of hemopexin promotes heme loading of splenic
myeloid cells
Recently, we demonstrated that Hx controls hepatic heme uptake and
thus limits heme accumulation in extrahepatic tissues, such as the vessel
wall and the heart,5 preventing heme-induced toxicity and tissue injury.5
Here we show that heme-challenged Hx-deficient mice, a model
for acute hemolytic event, accumulate more heme in the spleen
compared with heme-treated wild-type controls (Figure 1A). Consis-
tently, CD11b1cells (granulocytes and monocytes) and iron-rich cells
(macrophages) isolated from heme-treated Hx-null mice show a higher
heme content and increased mRNA and protein expression of HO-1,
L-ferritin, and Fpn (Figure 1B-G) and elevated mRNA levels of the
proinflammatory cytokine IL-6 (Figure 1H).These data suggest thatHx
limits heme uptake by white cell populations and that heme accumu-
lation affects the expression of genes involved in iron handling and the
inflammatory response.
To directly demonstrate that Hx reduces heme accumulation
specifically in macrophages, we measured heme levels in BMDMs
incubated with 5 mM heme bound to albumin (human/murine serum
albumin [HSA/MSA]) orHx (human) in a 1:1 ratio. Consistent with
our in vivofindings inHx-deficientmice, heme levelswere significantly
increased in BMDMs treated with heme-albumin compared with those
treated with heme-Hx (Figure 2A). Furthermore, monocyte/
macrophage-like cells (Raw264.7) treated with heme-albumin
accumulated higher levels of heme (Figure 2B). Similar results
were obtained when cells were exposed to the fluorescent
heme analog zinc-mesoporphyrin (ZnMP) bound to albumin or
Hx (supplemental Figure 1). Raw 264.7 cells treated with heme-
albumin showed increased mRNA and protein expression of HO-1
and FPN, increased protein expression of H- and L-ferritin, and HO
activity compared with heme-Hx treated cells (Figure 2C-H;
Table 1). In addition, we observed increased ROS production
(Figure 2I; supplemental Figure 2), as well as an enhanced
expression of IL-6 and TNFa in cells treated with heme-albumin
compared with heme-Hx (Figure 2J-K).
Taken together, these data demonstrate that Hx limits macrophage
heme overload and prevents the pro-oxidant and proinflammatory
effects triggered by heme in cellular assays and in vivo.
Heme and iron polarize macrophages toward an M1-like
proinflammatory phenotype
Based on the observation that ROS production and expression of
proinflammatory cytokines are elevated in heme-loaded macrophages
and that heme triggers sterile inflammation,18,54 we hypothesized that
heme may induce macrophage polarization toward an inflammatory
phenotype.
Table 1. Raw 264.7 macrophages heme-oxygenase activity assay
Treatment pmol Bilirubin/mg microsomal protein/hour
NT 181.165 6 20.091
Hx-heme 183.977 6 10.261
HSA-heme 264.141 6 5.582 vs NT; vs Hx-heme **P , .01
MSA-heme 246.633 6 11.161 vs NT; vs Hx-heme *P , .05
Heme 376.744 6 11.083 vs NT; vs Hx-heme *P , .05
The assay was performed on microsomes purified from Raw 264.7 cells
untreated (NT) or treated with 15 mM Hx-heme, HSA-heme, MSA-heme, or heme
alone for 5 hours. Values represent mean 6 SEM. *P , .05; **P , .01; ***P , .001.
n 5 4 for each sample.
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Figure 3. Heme induces macrophage polarization toward an M1-like phenotype, independently of the cell differentiation state. (A) M0, (B) M1, and (C) M2 BMDMs
were left untreated (NT) or exposed to 5 mM heme-BSA (1Heme; 1:1 ratio) for 12 hours. M1 and M2 markers are shown in the left and right column of each panel,
respectively. The expression of major histocompatibility complex class II (MHCII), CD86, CD14, and CD206 was analyzed by flow cytometry and is expressed in relative
fluorescence units (RFU) as fold change compared with untreated cells (NT). The mRNA levels of TNFa, Arginase-1, Ym1, and IL-10 were analyzed by qRT-PCR and
expressed in RQ, as fold change compared with untreated cells (NT). Results shown are the average of $3 independent experiments. (A direct comparison of expression
levels of M1 and M2 markers in M0, M1, and M2 BMDMs is shown in supplemental Figure 7, where fold changes are compared with untreated [NT] M0 cells). (D) Analysis of
the M1 markers MHCII and CD86 and the M2 marker CD206 and Arginase-1 in macrophages isolated from liver or spleen of untreated (NT) or heme-treated (hemin 30 mmol/kg)
wild-type mice. Macrophage were analyzed 15 hours or 15 days after intravenous heme injection (n 5 6). (E) Hematoxylin/eosin and Picrosirius red staining for collagen on
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To test this, we exposed cultured BMDMs (M0: not treated with
cytokines) to aged hemolytic RBCs (23107 cells) as a source ofHb, to
hemin (5 mM bound to bovine serum albumin [BSA], 1:1 ratio) or
to FeNTA (100 mM) and analyzed the expression of M1 and M2
macrophage polarization markers by flow cytometry (gating strategy;
supplemental Figure 3) and quantitative reverse transcriptase-
polymerase chain reaction (qRT-PCR). We show that incubation of
M0 BMDMs with aged RBCs increased the expression of M1
polarization markers, in particular MHCII and TNFa, and decreased
the expression of the M2 polarization marker CD206 (supplemental
Figure 4). Likewise, heme and FeNTA treatment causes the induction
of theM1markersMHCII, CD86, CD14, TNFa, IL-6, and IL1b and a
decrease in the M2 markers CD206, IL-10, and Arginase-1 (the last
withFeNTAonly) inM0BMDMs (Figure 3A; supplemental Figures 5,
6A, and 7). We next investigated whether heme and iron could also
affect the differentiation of macrophages that were exposed together
with cytokines that triggerM1orM2polarization.We demonstrate that
both hemin and FeNTA treatment enhanced the phenotype of
M1 macrophages (Figure 3B; supplemental Figures 6B and 7) and
shifted the differentiation of M2 macrophages toward an M1-like
phenotype (Figure 3C; supplemental Figures 6C and 7). Importantly,
protoporphyrin did not induce TNFa, suggesting a critical proinflam-
matory role for iron within the heme moiety (supplemental Figure 8).
Regulation of iron-related genes in M0, M1, andM2macrophages was
monitored to control for the efficacy of heme and FeNTA treatment
(supplemental Figure 9). These results demonstrate that heme in-
duces polarization of macrophages toward a M1-like proinflammatory
phenotype and that this effect is independent of the cell differentiation
state.
To assess whether heme alters macrophage plasticity in vivo, we
injected wild-type mice intravenously with heme (30 mmol/kg) and
analyzed iron levels and the expression of polarizationmarkers by flow
cytometry in spleen and liver macrophages, 15 hours or 15 days after
heme injection (gating strategy; supplemental Figures 10 and 11).
Importantly, 15 hours after heme injection, hepatic macrophages
showed iron deposition (data not shown) and an increased expression
of the M1 markers MHCII and CD86 and reduced levels of the M2
markers CD206 and Arginase-1 compared with nontreated mice.
Likewise, splenicmacrophages fromheme-treatedmice show increased
expression of CD86 and reduced levels of CD206 and Arginase-1
(Figure 3D). Modulation of most M1 and M2 markers was reduced 15
days after heme injection, indicating that heme-induced proinflamma-
tory activation of macrophages is a reversible event.
The polarization of macrophages into an M1 proinflammatory
phenotype contributes to the perpetuation of inflammation by recruit-
ment of circulating monocytes and leads to hepatocyte apoptosis
and fibrosis.55 Consistently, we show that repeated heme injections
(70 mmol/kg, 5 injections) cause the recruitment of a massive number
of inflammatory cells, deposition of collagen fiber, and liver damage
(Figure 3E).
We next assessed whether our findings are of pathophysiologic rel-
evance for a paradigmatic chronic hemolytic disorder such as SCD that
is hallmarked by a high amount of circulating Hb/heme, accelerated
erythrophagocytosis, and low endogenous levels of Hp and Hx.5 Our
analysis shows that liver macrophages from HbS sickle mice express
significant higher levels of the M1 markers MHCII, CD86, TNFa, and
IL-6 compared with HbA control mice and have enhanced macrophage
iron deposition (Figure 3F-G). Taken together, our data demonstrate that
heme triggers reversible proinflammatory phenotypic switching of
macrophages in vivo that could partially contribute to the inflammatory
state associated with chronic hemolytic conditions, such as SCD.
Activation of the TLR4 signaling pathway and ROS production
control heme-mediated phenotypic changes of macrophages
To studywhetherTLR4activation and/orROSproduction are involved
in heme-induced M1 polarization of macrophages, BMDMs were
treated either with heme alone or together with the TLR4 inhibitor
TAK-242 (400 nM) or the antioxidantN-acetylcysteine (NAC, 2mM).
Cotreatment of M0 BMDMs with heme and TAK-242 attenuated the
increase of the M1 markers MHCII, CD14, TNFa, IL-6, IL-1b, and
CD86 and the decrease of the M2 marker CD206, IL-10, and Ym1 in
comparison with heme treatment alone (Figure 4A; supplemental
Figures 5 and 12). Similarly, NAC prevented increased expression of
MHCII,CD14,TNFa, IL-6, IL-1b, andCD86andmildly compensated
for the decrease of CD206 and IL-10 following heme treatment
(Figure 4D; supplemental Figure 5). In addition, both TAK-242 and
NAC attenuated heme-mediated M1marker induction andM2marker
decrease inM2 BMDMs, whereas a milder effect was observed in M1
BMDMs (Figure 4B-F). Consistent with the data obtained by applying
the TLR4 inhibitor, BMDMs from TLR4-null mice show a strongly
attenuated increase of the M1 markers CD14, MHCII, IL-1b, and
TNFa on heme treatment. Additional NAC treatment of TLR4-null
BMDMs fully rescued the residual heme-mediated induction of these
markers (Figure 5A). Likewise, NACwas able to prevent iron-induced
M1 polarization in M0, M1, and M2 BMDMs (supplemental
Figure 13), indicating that the alteration of macrophage plasticity in
response to iron is mostly explained by its pro-oxidant properties.
To test whether ROS production and/or TLR4 activation are crucial
for the in vivo response of macrophages to heme, we challenged wild-
type mice either with heme alone or together with NAC (500 mg/kg
body weight) or TAK-242 (2 mg/kg body weight) and analyzed the
expression of macrophage polarization markers in isolated macro-
phages. In hepatic and splenic macrophages, cotreatment with NAC or
TAK-242 reduced the heme-induced upregulation of the M1 markers
MHCII and CD86 and attenuated inducible nitric oxide synthase
(iNOS) expression. In hepaticmacrophages, TAK-242 also diminished
heme-driven induction of IL-6 and TNFa andNACpartially recovered
CD206 downregulation (Figure 5B-C). The partial rescue observed
with both TAK-242 and NAC could be due to the use of suboptimal
doses of drugs applied or additional pathways contributing to heme/
iron-induced phenotypic switching of macrophages.
These findings suggest that both TLR4 activation and ROS
production control heme-mediated programming of macrophages toward
the M1 proinflammatory phenotype and that each of the 2 pathways is
indicated by a partially overlapping subset of M1 and M2 markers.
The heme scavenger Hx and the iron chelator DFO prevent
heme and iron-induced M1 polarization of macrophages
We next tested whether heme and iron scavengers prevent heme and
iron-induced macrophage polarization, respectively. M0 BMDMs
were exposed to hemolytic aged RBCs, heme, or FeNTA alone or
Figure 3 (continued) liver sections from heme-treated wild-type mice (70 mmol/kg, 5 injections; scale bar, 300-100 mm). Arrows indicate infiltrates (hem/eo) and collagen
(picrosirius). (F) Analysis of the M1 markers MHCII, CD86, TNFa, and IL-6 and the M2 marker CD206 in hepatic macrophages of control HbA and sickle HbS mice (n 5 4). The
expression of polarization markers in hepatic and splenic macrophages was analyzed by flow cytometry and is expressed in RFU as fold change compared with untreated wild-type
mice (NT) or HbA controls. (G) Perls’ staining for iron on liver sections from HbA and HbSmice (scale bar, 100 mm). Values represent mean6SEM. *P, .05; **P, .01; ***P, .001;
****P , .0001. Regulation of iron-related genes in M0, M1, and M2 macrophages was monitored to control for the efficacy of heme and FeNTA treatment (supplemental Figure 9).
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Figure 4. The TLR4 inhibitor TAK-242 and the antioxidant NAC attenuate heme-induced M1 polarization of macrophages. (A,D) M0, (B,E) M1, and (C,F) M2 BMDMs
were left untreated (NT) or exposed to 5 mM heme-BSA (1Heme; heme-BSA 1:1 ratio) with or without (A-C) 400 nM TAK-242 and (D-F) 2 mM NAC for 12 hours. M1 and M2
markers are shown in the left and right column of each panel, respectively. The expression of MHCII, CD14, and CD206 was analyzed by flow cytometry and expressed in
RFU as fold change to nontreated (NT) cells. mRNA levels of TNFa, Arginase-1, and IL-10 were analyzed by qRT-PCR and expressed in RQ, as fold change to untreated (NT)
cells. Results shown are representative of 3 independent experiments. Values represent mean 6 SEM. *P , .05; **P , .01; ***P , .001; ****P , .0001.
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Figure 5. TLR4 signaling and ROS production contribute to heme-induced M1 proinflammatory phenotypic switching of macrophages. (A) M0 BMDMs were prepared
from wild-type and TLR4-null mice and left untreated (NT) or exposed to 5 mM heme-BSA (1Heme; heme-BSA 1:1 ratio) with or without 2 mM NAC or to 5 mM heme-Hx
(Hx; heme-Hx 1:1 ratio) for 12 hours. M1 and M2 markers are shown in the left and right column of each panel, respectively. The expression of CD206, CD14, CD86, and MHCII
was analyzed by flow cytometry and expressed in RFU as fold change to untreated cells (NT). mRNA levels of TNFa and IL-1b were analyzed by qRT-PCR and expressed in RQ,
as fold change to untreated cells (NT). Results shown are representative of 3 independent experiments. (B-C) Analysis of the M1 markers MHCII, CD86, iNOS, IL-6, and TNFa and
the M2 markers Arginase-1 and CD206 in macrophages isolated from (B) liver or (C) spleen of wild-type mice untreated (NT) or treated with heme (heme-BSA 30 mmol/kg;
15 hours) with or without TAK-242 (2 mg/kg) or NAC (500 mg/kg) (n 5 8). The expression of polarization markers in hepatic and splenic macrophages was analyzed by flow
cytometry and is expressed in RFU as fold change compared with untreated wild-type mice (NT). Values represent mean6 SEM. *P, .05; **P, .01; ***P, .001; ****P, .0001.
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Figure 6. Hx prevents M1 polarization of macrophages in response to heme. (A) M0, (B) M1, and (C) M2 BMDMs were left untreated (NT) or exposed to 5 mM heme-BSA
(1Heme; heme-BSA 1:1 ratio) or 5 mM heme-Hx (Hx; heme-Hx 1:1 ratio) for 12 hours. M1 and M2 markers are shown in the left and right column of each panel, respectively.
Results shown are the average of $3 independent experiments. (D) Analysis of the M1 markers MHCII and CD86 and the M2 marker CD206 in macrophages from liver and
spleen of wild-type mice that remained untreated or were treated with heme-HSA or heme-Hx (complex 15 mmol/kg; 15 hours) (n5 5). The expression of MHCII, CD86, CD14,
and CD206 was analyzed by flow cytometry and expressed in RFU as fold change to untreated cells or untreated wild-type animals (NT). mRNA levels of TNFa, Arginase-1,
Ym1, and IL-10 were analyzed by qRT-PCR and expressed in RQ, as fold change to untreated cells (NT). (E) Perls’ staining for iron on liver and spleen sections from wild-type
mice that were treated with heme-HSA or heme-Hx (scale bar, 20-50 mm). Arrows indicate iron-loaded Kupffer cells. Values represent mean 6 SEM. *P , .05; **P , .01;
***P , .001; ****P , .0001.
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together with Hx (100 mM with RBCs; 5 mM with heme) or DFO
(100 mM with FeNTA). Treatment with Hx or DFO diminished the
increase of some M1 polarization markers in BMDMs following
treatmentwithhemolyticRBCs (supplementalFigure14). Inaddition,Hx
and DFO prevented the heme- and iron-mediated induction of the M1
markersMHCII, CD86, CD14, and TNFa and the decrease of someM2
markers, suchasCD206, IL-10, andArginase-1 (the last forFeNTAonly)
inM0 BMDMs (Figure 6A; supplemental Figure 15A). Importantly,
the expression of polarization markers remained unaltered following
treatment with Hx and DFO alone (supplemental Figure 16). Similar
data were obtained whenM1 orM2macrophages were exposed to heme
or FeNTA in the presence of Hx or DFO (Figure 6B-C; supplemental
Figure 15B-C). Interestingly, treatment with Hx and DFO improved the
survival of BMDMs exposed to heme and iron, respectively (Table 2).
To assess the potential of heme scavengers for protecting macro-
phages from heme-triggered polarization in vivo, we injected wild-type
mice with heme bound to the low-affinity scavenger, HSA, or the
high affinity scavenger, Hx, and analyzedmacrophage polarization
markers. Interestingly, hepatic macrophages derived from mice
treated with heme-Hx showed a blunted induction of the M1
markers MHCII and CD86 compared with cells from animals treated
with heme-HSA (complex 15 mmol/kg; 15 hours). Similarly, the heme-
mediated induction of the M1 marker CD86 and downregulation of the
M2 marker CD206 are rescued in splenic macrophages from heme-Hx-
treatedmice comparedwith heme-HSA–challenged animals (Figure 6D).
Perls’ staining of liver and spleen sections demonstrates thatmacrophages
accumulated more iron following heme-HSA treatment compared with
heme-Hx treatment (Figure 6E).
These results suggest that the sequestration of heme and iron by
specific scavengers counteracts the proinflammatory state of macro-
phages associated with M1 differentiation.
Hemopexin therapy ameliorates the proinflammatory status
of macrophages in a mouse model of sickle cell disease
We next evaluated whether Hx administration is able to attenuate the
proinflammatory status of macrophages in a murine disease model for
SCD. The treatment of sickle mice with human Hx (4 mg Hx intraperi-
toneally once a week, for 3 weeks) decreased the expression of the M1
markers MHCII, CD86, iNOS, and IL-6 in hepatic macrophages
compared with HbA control mice, whereas the M2 marker CD206 was
not significantly altered.Higher expressionofArginase-1maybe related
to the liver fibrotic damage that SCDmice tend to develop, as Arginase-1
contributes to collagen synthesis. Interestingly, the attenuated levels of
Arginase-1 following Hx injection may be a consequence of reduced
heme-mediated oxidative tissue damage and fibrosis (Figure 7A).
Proinflammatory activation of hepatic resident macrophages is
known to induce blood monocyte recruitment, which enhances
cytokine production. These cytokines cause hepatocyte apoptosis and
promote fibrosis by inducing activation and transdifferentiation of
hepatic stellate cells (HSCs) into myofibroblasts, which is the major
collagen-producing cell type. Here we show that Hx treatment de-
creases expression of the M1 cytokine TNFa, the monocyte chemo-
attractant protein (MCP)1, and the profibrotic and mitogenic cytokines
transforming growth factor (TGF)b and platelet-derived growth
factor (PDGF) in the liver of sickle mice. Moreover, Hx administration
increases hepatic expression of the matrix metalloproteinases
MMP-9, MMP-12, and MMP-13 (mostly expressed by M2 macro-
phages). It further increases the expression of a marker for resting HSCs,
synaptophysin, and reduces the expression of a marker for activated
myofibroblast-like HSCs, smooth muscle actin (SMA) (Figure 7B).
Despite these favorable alterations observed in Hx-treated sickle
mice, liver damage as measured by collagen deposition and apoptosis of
hepatocytes could not be reverted (supplemental Figure 17). In 2- to 3-
month-old sickle mice, liver damage is already established, and thus the
right timing and dosage of Hx administration may need to be optimized.
We therefore next analyzed heme-Hx-treated wild-type mice that
showed decreased hepatic expression of collagens, TGFb, PDGF,
SMA, and the tissue inhibitor of MMPs, TIMP2, as well as increased
expression of theM2polarizing colony stimulating factor-1 andMMPs
comparedwith heme-HSA–treatedmice (Figure 7C). In addition,wild-
type mice treated with heme-Hx showed reduced liver collagen de-
position and hepatocyte apoptosis compared with animals treated
with heme-HSA (complex 5 mmol/kg; 7 injections over 2 weeks)
(Figure 7D). Consistently, heme-treated Hx-null mice show increased
inflammatory cell recruitment and tissue damage in the liver compared
with heme-treated wild-type mice (70 mmol heme/kg; 5 intravenous
injections) (supplemental Figure 18).
Taken together, these data suggest that Hx administration de-
creases heme-driven proinflammatory activation of macrophages. As a
consequence, the release of inflammatory cytokines that drive monocyte
recruitment and HSC transdifferentiation is reduced, and expression of
MMPs that favors scar regression is increased. This results in the
resolutionof inflammationanddecreasedhepatic collagendepositionand
cell apoptosis. In conclusion, an Hx-based therapy shows beneficial
effects, in that it counteracts heme-inducedproinflammatory activationof
macrophages and attenuates some of its pathophysiologic consequences,
suchas chronic inflammation, hepaticfibrosis, and apoptosis (Figure7E).
Discussion
In this study, we show that various sources of heme (hemolytic RBCs,
free heme) and iron activate macrophages to differentiate toward an
M1-like proinflammatory phenotype, which is hallmarked by the
production of inflammatory cytokines and ROS. The underlying
mechanisms involve ROS production and TLR4-controlled signaling.
Table 2. Viability of BMDMs exposed to heme, FeNTA, and hemolytic RBCs in the presence or absence of Hx and DFO
NT 1Heme-BSA 1 Heme-Hx
M0 89.07 6 2.443 51.13 6 5.032 vs NT P , .0001 86.25 6 3.036 vs Heme-BSA P , .0001
M1 63.88 6 3.785 46.17 6 2.569 vs NT P , .001 71.95 6 2.737 vs Heme-BSA P , .0001
M2 89.85 6 1.699 52.08 6 2.788 vs NT P , .0001 90.78 6 0.895 vs Heme-BSA P , 00001
1FeNTA 1 FeNTA-DFO
M0 94.40 6 0.503 72.03 6 5.341 vs NT P , .05 90.23 6 4.670 vs FeNTA P , .05
M1 61.30 6 6.584 45.07 6 5.007 vs NT not significant 55.65 6 6.986 vs FeNTA not significant
M2 93.40 6 1.320 73.13 6 3.464 vs NT P , .01 88.80 6 2.70 vs FeNTA P , .05
1RBC 1 RBC-Hx
M0 93.98 6 0.349 83.02 6 0.837 vs NT P , .0001 88.75 6 0.150 vs RBC P , .001
Cell viability was assessed by flow cytometry using 7AAD. Viability is reported as percentage viable cells over the total number of analyzed cells.
482 VINCHI et al BLOOD, 28 JANUARY 2016 x VOLUME 127, NUMBER 4
For personal use only.on January 29, 2016. by guest  www.bloodjournal.orgFrom 
Figure 7. Hx rescues heme-induced M1 polarization of macrophages in a mouse model of sickle cell disease. (A) Analysis of the M1 markers MHCII, CD86, iNOS, and
IL-6 and the M2 markers CD206 and Arginase-1 in macrophages from liver of HbA mice and HbS mice that remained untreated or were treated with Hx (4 mg intraperitoneally
once a week for 3 weeks) (n 5 5). The expression of polarization markers was analyzed by flow cytometry and is expressed in RFU as fold change to HbA animals. (B)
qRT-PCR analysis of hepatic mRNA levels of TNFa, MCP-1, TGFb, PDGF, MMP-9, MMP-12, MMP-13, synaptophysin, and SMA in HbA mice and HbS mice that remained
untreated or were treated with Hx (4 mg intraperitoneally once a week for 3 weeks) (n5 7). (C) qRT-PCR analysis of hepatic mRNA levels of collagen1a1, collagen1a2, TGFb,
PDGF, SMA, colony stimulating factor-1, TIMP2, MMP-12, and MMP-13 in wild-type mice that remained untreated or were treated with heme-HSA or heme-Hx (complex
5 mmol/kg, 7 injections over 2 weeks) (n 5 5). (D) Picrosirius red staining for collagen and Tunel staining for apoptosis on liver sections from wild-type mice that remained
untreated or were treated with heme-HSA or heme-Hx (complex 5 mmol/kg, 7 injections over 2 weeks) (scale bar, 300-100 mm). Arrows indicate collagen (picrosirius) and
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We further demonstrate that heme/iron-controlled macrophage polar-
ization is preventable by heme scavengers or iron chelators. These
findings are of relevance for diseases that are characterizedbyexcessive
circulating Hb, heme, and/or iron levels and macrophage iron loading.
Macrophages show high plasticity in response to the cytokine
composition of themicroenvironment.Our data show thatHb, heme, or
iron in themicroenvironment additionally affectmacrophage plasticity.
This finding extends previous work that demonstrates that cytokines
that drive M1 or M2 polarization determine iron handling.46,47,56 In
those studies,M1macrophages showan iron retention phenotype and a
gene expression profilewith low expression ofHO-1, FPN, andCD163
and high expression of ferritin. On the other hand, M2 macrophages
show higher expression ofHO-1, FPN, andCD163 and low expression
of ferritin, likely associated with an iron release phenotype with
increased iron uptake, recycling, and export activity. Our data are not
entirely consistent with these observations, in that transferrin receptor 1
mRNA levels are higher in M2 compared with M1 macrophages,46,47
as reported,44,45 whereas HO-1 and FPN mRNA levels do not differ
(supplemental Figure 9). These differences may be explained by the
protocols applied for monocyte/macrophage differentiation. Despite
differences in gene expression patterns, our findings, together with
those by Recalcati et al46 and Corna et al,47 strengthen the concept that
macrophage function and iron metabolism are tightly interconnected.
Our study further demonstrates that the functional consequences of
macrophage exposure to cytokines and iron integrate and eventually
potentiate each other, according to their relative amounts available in
the microenvironment, rather than having a mutually exclusive effect
on macrophage polarization. It is important to note that heme and
iron seem to exert a dominant effect on macrophage polarization,
inducing a shift toward a proinflammatory phenotype. In particular, the
polarization program of macrophages in response to cytokines can be
enhanced (M1→M11) or even shifted (M2→M1) by an additional
exposure to a heme or an iron source (Figure 7D). Therefore, heme/iron
accumulation is expected tomodulate the phenotypical differences that
macrophages acquire in response to the environmental stimuli.
Recently, a key role for heme in controlling monocyte differenti-
ation into macrophages was demonstrated. This process is increased
during pathologic hemolysis.57 Here we demonstrate that heme
additionally affects the phenotype of differentiated macrophages. An
involvement of Hb, heme, and iron in macrophage polarization was
postulated in recent studies. In models of chronic venous leg ulcers
and wound healing, macrophage iron overload correlates with a
proinflammatory M1 phenotype, TNFa, and hydroxyl radical pro-
duction.58 Nieuwenhuizen et al59 observed a decrease in M2 and an
increase in M1 macrophages in the red pulp of the spleen and in
synovial tissue in hemophilic mice. The authors speculated that this
results from an increased number of damaged RBCs and a higher level
of circulating Hb following hemarthrosis. The data presented here may
explain thesefindings.Macrophagepolarization has alsobeen analyzed
in atherosclerotic plaques, where erythrophagocytosis in hemorrhagic
areas represents an important source of iron for macrophages.60-64
Hemorrhage-associated macrophages (HA or M-hem) in atheroscle-
rotic lesions express high levels of the Hb-Hp scavenger receptor
CD163,HO-1, andFPN, accounting for an increased capacity to handle
Hb, facilitated heme catabolism and reduced intracellular free iron.
Therefore, in atheroma, theHb-Hp complexmightmodelmacrophages
toward a protective HA-macrophage subtype with increased capacity
to handle Hb, as well as antioxidative and antiatherogenic properties.
In this regard, the saturation of the Hp system is expected to be
detrimental, leading to uncontrolled Hb uptake and macrophage
activation.
Consistently, we show that the saturation of the Hx system leads to
heme accumulation and proinflammatory activation of macrophages.
Heme released from cell-free Hb is normally bound to Hx and
internalized by hepatocytes, via the LRP1 receptor,65 or other thus far
unidentified and more specific scavengers. Hx-mediated heme scaveng-
ing and hepatic detoxification ensure protection of several extrahepatic
tissues against heme toxicity.5,6 Herewe show that this protective effect
extends toward macrophages and is reduced in disorders where
the Hx binding capacity is overwhelmed and its synthesis is not
appropriate compared with the rate of consumption.5,15 This is the case
in amousemodel of SCD,which is hallmarked by hemolysis, increased
circulating Hb/heme, and low levels of Hp and Hx and shows elevated
hepatic macrophage iron levels and M1 polarization.
In our study we further provide mechanistic insight into how heme
and iron cause phenotypic changes ofmacrophages. Herewe show that
this process depends on the production of ROS and the activation of the
TLR4 signaling pathway. This is strengthened by the observation that
heme-mediated induction of M1 markers is attenuated in TLR4-null
BMDMs and fully abolished when these cells are additionally exposed
to NAC. Importantly, by scavenging free heme, Hx prevents heme-
induced M1 macrophage polarization and thus avoids both TLR4
activation and ROS formation. These observations are in line with
recent studies demonstrating antioxidant and anti-inflammatory prop-
erties of Hx,5,6,66-68 as well as its ability to prevent heme-triggered
TLR4 activation and TNFa production.17,54 Thus, Hx treatment
provides a clear advantage over pharmacologic approaches in that it
combines antioxidant properties together with inhibitory effects on the
proinflammatory pathways induced by heme.
Our findings are therefore expected to be relevant for those
pathologies in which Hb and heme are released from the RBCs,
systemically or locally, and Hp/Hx levels are reduced, thus leading to
the activation of innate immune cells and the production of ROS and
inflammatory cytokines. We suggest that the extent of inflammation
associatedwith hemolytic disordersmaydependon intravascular rather
than extravascular hemolysis. In SCD, hemolysis occurs both intra- and
extravascular and macrophage exposure to “extracellular” heme
triggers inflammation via TLR4 stimulation. In other conditions,
such as hereditary spherocytosis, hemolysis is mainly extravas-
cular and RBCs are presented intact to reticuloendothelial system
macrophages, thus explaining the milder signs of inflammation in
these patients. The extent of inflammation in different hemolytic
disorders may therefore depend on how macrophages get in
contact with heme, either with heme contained within intact RBCs or
in the form of free or bound Hb/heme. Controlled iron accumulation
inmacrophages, as a consequence of erythrophagocytosis or uptake
of iron-bound transferrin, is not expected to represent a stimulus to
trigger M1 polarization in vivo.
Figure 7 (continued) apoptotic cells (tunel). Results shown are representative of 3 independent experiments. Values represent mean 6 SEM. *P , .05; **P , .01;
***P , .001; ****P , .0001. (E) Model for macrophage differentiation in response to Hb, heme, and iron and its protection by heme and iron scavengers. Hb derived from
hemolytic RBCs, heme, and iron promotes macrophage differentiation toward an M1-like proinflammatory phenotype, via ROS production and TLR4 signaling activation. This
effect is independent of the differentiation state of the macrophages (eg, M0, M1, or M2). Interestingly, M1 macrophages show a potentiated M1 phenotype (M11), and even
anti-inflammatory M2 macrophages can be shifted to an M1-like proinflammatory phenotype in response to heme and iron, suggesting that these signals dominate over those
triggered by cytokines. Heme or iron scavengers, such as hemopexin (Hx) or desferrioxamine (DFO), protect macrophages from heme or iron-induced M1 polarization,
reducing iron loading, cytokine production, and ROS formation.
484 VINCHI et al BLOOD, 28 JANUARY 2016 x VOLUME 127, NUMBER 4
For personal use only.on January 29, 2016. by guest  www.bloodjournal.orgFrom 
Wepropose that themodulation ofmacrophage polarization toward
a less inflammatory phenotype may represent an interesting pro-
phylactic or therapeutic approach in hemolytic disorders. This could be
achieved by administration of heme and/or iron scavengers. Recent
studies in mouse models of hemolytic disorders demonstrated that the
therapeutic administration of Hx increases hepatic heme recovery and
detoxification and successfully counteracts heme-induced endothelial
activation and dysfunction.5 Similarly, in a SCD mouse model, vas-
cular stasis and respiratory failure due to acute chest syndrome were
prevented by treatment with purified or recombinant Hx.17,69 Here we
show that the administration of Hx attenuates the induction of in-
flammatory cytokines and M1 polarization markers in macrophages
triggered by heme. The activation of macrophages toward a proin-
flammatory phenotype in the liver contributes to the induction of
hepatocyte apoptosis, perpetuation of inflammation via leukocyte
recruitment, and promotion of fibrosis via cytokine release and HSC
activation.55 Previously, we showed that Hx therapy attenuates hepatic
lipid peroxidation, leukocyte recruitment, and the expression of in-
flammatory cytokines, such as IL-6 and TNFa, in SCD.5,6 Here we
additionally show that Hx administration reduces the expression of the
chomattractant MCP-1, the profibrotic TGFb and PDGF, and the
activation of HSCs in sickle mice, suggesting that Hx-mediated heme
scavenging counteracts heme-driven hepatic fibrosis and tissue injury.
Our data support the idea that heme-induced phenotypic switching
of macrophages toward a proinflammatory phenotype can contribute
to the exacerbation of inflammation and chronic tissue injury in he-
molytic disorders and that Hx therapy could alleviate these patho-
physiologic consequences by preventing macrophage inflammatory
activation.3,4,9,40,50,70,71
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Supplemental Material and Methods  
 
Mice treatment 
All mice analysed were between 2/3 months of age. Mice were treated with heme-albumin (20-
30mol/kg). Pre-treatment with NAC (Sigma, 500mg/kg body weight) or TAK-242 (2mg/kg 
body weight) was performed 30 min before infusion with heme-albumin. For rescue experiments, 
heme bound 1:1 to human plasma-derived Hx or albumin (CSL Behring, Switzerland) was 
injected at a dose of 5-15 mol/kg. HbS sickle mice were treated with 4 mg human Hx ip, once a 
week for 3 weeks. Mice were sacrificed 1h, 6h, 15h or 15 days after heme injection, tissue 
samples were collected and either directly analysed or snap frozen until further analysis. 
Heme (hemin chloride, Frontier Scientific, Logan, Utah) was dissolved in 0.1 N NaOH and 
diluted in PBS at a final concentration of 10 mmol/L. pH was adjusted at 7.4 with 0.1 N HCl. 
Freshly prepared heme was injected into the tail vein of mice at a dose of  30-70 mol/kg. 
 
Heme and ZnMP Content Quantification 
Heme content in spleen, splenic macrophages, BMDMs and Raw 264.7 cells was quantified 
fluorometrically by the method of Sassa (Sassa et al). Briefly, tissues were homogenized in 
phosphate buffered saline (PBS) and the protein content was determined by using the Bio-Rad 
protein assay system (Bio-Rad, Munchen, Germany). 10 g of protein samples were incubated 
with 0.5 ml of 2 M Oxalic Acid (Sigma-Aldrich) at 95°C for 30 min. Samples were subsequently  
centrifuged at 14000 rpm for 5 min. Fluorescence emission in the supernatant was determined 
spectrofluorimetrically (Glomax, Promega). Excitation and emission wavelengths were set at 405 
and 662 nm, respectively. The background was evaluated by measuring fluorescence in non-
 2 
 
boiled samples. ZnMP was quantified in BMDM extract by fluorescence, with an excitation 
wavelength of 407 nm and an emission wavelength of 578 nm (Glomax, Promega). 
 
BMDM Preparation 
The murine monocyte/macrophage Raw264.7 cell line (ATCC TIB-71) cultured in  DMEM 
medium supplemented with 10% FBS and 1% Penicillin/Streptomycin (Gibco). BMDMs were 
differentiated in vitro from bone marrow stem cell progenitors for one week using RPMI medium 
supplemented with 10 ng/ml M-CSF (M9170, Sigma-Aldrich), 10% FBS and 1% 
Penicillin/Streptomycin (Gibco). BMDMs were co-treated with 100 ng/ml LPS plus 20 ng/ml 
IFN, to obtain M1 macrophages, and 20 ng/ml IL-4 plus 20 ng/ml IL-10, to obtain M2 
macrophages, together with heme or iron for 12 and 18 hours, respectively. For each independent 
experiment, BMDMs were prepared from three different mice. 
 
Quantitative Real-Time Polymerase Chain Reaction Analysis 
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen) and from liver using 
Trizol (Qiagen). 0.5 to 1g of total RNA was reverse transcribed by using RevertAid H Minus 
reverse transcriptase (Thermo Scientific), random primers (Invitrogen) and dNTPs (Thermo 
Scientific). qRT-PCR was performed on a Step One Plus Real Time PCR System (Applied 
Biosystems, California, USA). Primers and probes were designed using the ProbeFinder software 
(www.roche-applied-science.com) (See TableS1). Differences in Relative Quantity (RQ) are 
shown as fold-change compared to the control condition (untreated wild-type mice or cells, NT). 
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Protein Extraction and Western Blotting  
Protein extracts were prepared as previously reported and protein concentration was determined 
using the Bio-Rad protein assay system (Bio-Rad, Munchen, Germany). 50 g of total protein 
extracts were separated by 8-12% SDS-PAGE and analyzed by Western blotting using antibodies 
against HO-1 (Stressgen, Victoria, Canada), L-/H-Ferritin (kindly provided by Sonia Levi), FPN 
(Alpha Diagnostic Intl. Inc., San Antonio, TX), vinculin (produced in the laboratory at the 
Molecular Biotechnology Center in Turin) and actin (Santa Cruz). Densitometric analysis is 
reported in Arbitrary Unit (AU), as ratio to the untreated (NT) sample (AU=1). 
 
Measurement of intracellular ROS accumulation 
Accumulation of ROS in Raw 264.7 cells was assessed by using the oxidant-sensitive fluorescent 
dye 29,79-dichlorodihydrofluoroscein diacetate (H2DCFDA; Molecular Probes, Inc., Eugene, 
OR). H2DCFDA penetrates easily into the cells. Upon crossing the cellular membrane, 
H2DCFDA undergoes deacetylation by intracellular esterases producing a non-fluorescent 
compound that becomes highly green fluorescent following oxidation by intracellular ROS. 
Within the cell the probe reacts with ROS to form fluorescent 28,78 dichlorofluoroscein (DCF), 
which is detected with spectrofluorometry. Raw 264.7 cells untreated or treated for 6/15/20 hrs 
with 10/15 M Hx-heme, HSA-heme or heme alone were incubated with 5M H2DCFDA in 
Hanks’ balanced salt solution (HBSS) for 30 min at 37 °C under 5% CO2 atmosphere. Then cells 
were washed twice with HBSS, trypsinyzed and analyzed by flow cytometry using a FACS flow 
cytometer or a fluorimeter plate reader (Promega). Fluorescence was recorded in the fluorimeter 
reader at excitation and emission wavelengths of 485 and 530 respectively. The background 
fluorescence caused by buffer and DCF was subtracted from the total fluorescence in each well 
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generated by cell extract in presence of DCF. Fluorescence intensity units were normalized by 
mg of cell proteins and expressed as arbitrary fluorescence units/mg protein. 
 
Heme Oxygenase activity assay 
Heme-Oxygenase activity was measured by spectrophotometric determination of bilirubin 
produced from hemin added as the substrate. Raw 264.7 cells were lysed with a hypotonic buffer 
(0.1 M potassium phosphate, 2mM MgCl2, Complete Protease Inhibitor Cocktail, Roche 
Diagnostics Corp., Milano, Italy, pH 7.4) for 15’ on ice. After brief sonication. 0.6 M sucrose 
was added to cell lysates in order to obtain an hysotonic solution (final 0.25 M sucrose). Lysates 
were centrifuged at 1000 x g for 10 min at 4°C to pellet nuclei, and supernatants centrifuged at 
12000 g for 15 min at 4 °C to pellet mitochondria. Finally, supernatants were ultracentrifuged at 
105000 g for 1 hour at 4°C. Microsomal fractions were resuspended in 100 mM potassium 
phosphate buffer pH 7.4, containing 2 mM MgCl2 and Complete protease inhibitor. Protein 
concentration was determined using a small aliquot of these suspensions (Bio-Rad). The 
microsomal supernatant fraction (cytosol) from the liver of a normal rat served as source of 
biliverdin reductase. Liver supernatant was prepared fresh from rat liver by homogenization in 
0.1 M sodium citrate buffer, pH 5, containing 10% glycerol. HO-1 activity assay was carried out 
by incubating 600 g microsome proteins with a reaction mixture containing 1 mM NADPH, 2 
mM glucose-6-phosphate, 1U glucose-6-phosphate dehydrogenase (Sigma-Aldrich), 25 M 
hemin, 2 mg of rat-liver cytosol and 100 mM potassium phosphate buffer, pH 7.4 (400 l final 
volume). The reaction was conducted in the dark for 1h at 37 °C and terminated by placing tubes 
on ice for 2 min. The amount of bilirubin  was determined by the difference in absorption 
between 464 and 530 nm (extinction coefficient, 40 mM
-1
 cm
-1
 for bilirubin). HO activity was 
expressed in picomoles of bilirubin formed per milligram microsomal protein per hour.  
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Cell heme treatment 
Heme or ZnMP was dissolved in DMSO to obtain a 4 mM stock solution. Heme was mixed 1:1 
with human albumin (HSA, CSL Behring), murine or bovine albumin (Sigma-Aldrich) or Hx 
(CSL Behring, Switzerland), in order to obtain 25 M complex solutions, and incubated for 30 
minutes at 37°C. These solutions were diluted to 5 M in culture medium for cell treatments. 
FeNTA was prepared by mixing a 10mM solution of FeCl3 with a 40mM solution of NTA. DFO 
was dissolved in water and then added to FeNTA at a 1:1 ratio for 30 minutes at 37°C. These 
solutions were diluted to 100 M in culture medium for cell treatments. N-acetylcysteine (NAC, 
Sigma-Aldrich) was dissolved in water to prepare a 100 mM stock solution and used at a final 
concentration of 2.5 mM in cell medium. TAK-242 was dissolved in DMSO and further diluted 
to a stock solution of 300 M and used at a final concentration of 400 nM on cells.  
 
Hemolytic RBC preparation  
Mice blood was collected on ethylenediaminetetraacetic acid (EDTA). After 3 washes with 
phosphate buffer saline (PBS), mouse red blood cells (RBC) were resuspended in Hepes buffer 
(10 mM Hepes, 140 mM NaCl, BSA 0.1%, pH 7.4). For in vitro RBC ageing, cells (2x10
8
 
cells/ml in Hepes buffer) were incubated overnight at 30ºC with 2,5 mM calcium and 0,5 mM of 
the ionophore A23187 (Calbiochem, CA, USA). Treated RBC were then centrifuged (1500 rpm 5 
min), washed twice with PBS and resuspended in RPMI medium (2x10
7
 cells/ml). After 6h of 
incubation, macrophages were washed 3 times with HBSS to remove free RBCs and lysed for 
RNA extraction or harvested for flow cytometry analysis. The extent of hemolysis of aged RBCs 
was evaluated measuring heme levels in the medium used to treat cells. 
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Isolation of splenic myeloid cells 
 Granulocytes, monocytes and macrophages were isolated from a cell suspension of the spleen by 
using anti-CD11b microbeads and applying a magnetic field (MACS), following manufacturer’s 
instructions (Miltenyi Biotech, Bergisch Gladbach, Germany). With this approach, CD11b
+
 
granulocytes and monocytes (selected by immunomagnetic isolation with CD11b antibody) and 
CD11b
low
 iron-rich ferromagnetic macrophages (selected by a magnetic field only) were isolated.  
 
 
 
 
 
 
 
 
 
 
Macrophage isolation from spleen and liver  
Macrophages were isolated from spleen or single hepatic lobules. One third of the spleen was 
passed through a 100 μm Cell Strainer (BD). A single liver lobe was perfused with PBS and then 
Hepatocyte Liver Digest Medium (Gibco). Perfusion with the Digest Medium was kept until the 
liver lobe felt very soft. Subsequently, the lobe was disrupted and the cell suspension forced 
through a 100 μm Cell Strainer. Liver cells were centrifuged at 60 g for 2 minutes and then at 
100g for 2 additional minutes, to separate hepatocytes (pellet) from non-hepatocytic cells 
(supernatant). Both the liver supernatant and spleen cell suspension were then added to a RBC 
lysis solution to remove RBCs. Afterwards, spleen and liver suspension was centrifuged at 1700 
rpm 5 min 4°C. Spleen and hepatic macrophage enriched fractions were then stained for flow 
cytometry analysis or kept frozen for mRNA analysis.  
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Flow cytometry 
BMDMs and ex vivo macrophages were incubated with Fc-γ receptor blocking solution 
(CD16/32) and next stained with anti-mouse CD206-FITC, CD86-PE, MHC II-PacificBlue, 
CD14-APC-Cy7, F4/80-APC, CD45.2-Pacific Blue or GR1-APC-Cy7, 7AAD (BioLegend, 
California, USA) and CD11b-Horizon V500 (BD Biosciences). For the intracellular staining, 
cells were washed and then subjected to surface antigen staining using the antibodies described 
for flow cytometry (after blocking in Fc-γ receptor blocking solution). Cells were fixed and 
permeabilized in Perm/wash solution (eBioscience) according to manufacters instruction and then 
stained in Permeabilization Buffer (eBioscience). Intracellular cytokine staining was performed 
using an anti-mouse TNFα-FITC (Becton Dickinson), IL-6-PE (Biolegend), iNOS-FITC (Becton 
Dickinson) and Arginase-1-PE (R&D systems). Data were acquired by a FACS Aria flow 
cytometer (BD, Biosciences) and analysis was performed using the FlowJo Software (Tree Star 
Inc). The expression of surface markers is shown as Relative Fluorescence Units (RFU), whereby 
the geometric mean fluorescence intensity (MFI) of the cells stained with the isotype-matched 
antibody was subtracted from the MFI of those stained with the specific antibody. Differences in 
RFU are expressed as fold-change to the control condition (untreated cells or mice, NT).  
 
DAB-enhanced Perls´ staining 
Liver and spleen obtained from adult mice were fixed for 24 hr in 10% neutral buffered formalin 
(Sigma), dehydrated, and paraffin embedded. Tissue sections (5 μm) were mounted on Polysine 
slides (Thermo Scientific) and stained with Accustain Iron Stain No. HT20 (Sigma-Aldrich) 
following manufacturer’s instructions. The Perls´ blue staining was further enhanced using the 
DAB peroxidase substrate kit SK-4100 (Vector Laboratories, Burlingame, CA). 
 
 8 
 
Picrosirius Red staining for collagen 
Liver sections were stained in  Weigert's haematoxylin (Sigma, HT1079), followed by Sirius red 
solution for one hour (Direct Red 80", Sigma, 365548). Slides were washed in two changes of 
saturated aqueous solution of picric acid (1.3% in water; Sigma, P6744-1GA), dehydrated and 
mounted. 
 
TUNEL staining for apoptosis 
For the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, 
liver sections were stained using the In Situ Cell Death Detection kit (Roche Molecular 
Biochemicals, Indianapolis, IN), according to the manufacturer's instructions. Slides were 
counterstained with Nuclear Fast Red (Dako) and mounted. 
 
Supplementary Text  
Raw 264.7 cells were incubated with the heme fluorescent analog ZnMP complexed with Hx or 
Albumin (of different origin, human serum albumin-HSA or murine serum albumin-MSA) or 
alone. ZnMP uptake was higher in cells treated with ZnMP-Albumin or ZnMP alone than in cells 
incubated with ZnMP-Hx (Figure S1A,B). ZnMP is an heme analog able to inhibit HO activity, 
therefore its amount in the cell represents the fraction of molecule that is taken up and 
accumulated, without being degraded. Comparing the heme and the ZnMP uptake experiments, it 
is worth noting that Hx allows heme uptake in the cell (ZnMP-Hx uptake line, Figure S1A) to an 
amount that could be rapidly degraded by HO, keeping constant the total intracellular heme levels 
(heme-Hx uptake line, Figure 2B) 
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Supplementary Figures: 
 
Figure S1. Hx limits ZnMP uptake in Raw 264.7 cells. (A) ZnMP uptake in Raw264.7 cells 
untreated (0 min) or incubated with 5M Hx-ZnMP, HSA-ZnMP, MSA-ZnMP or ZnMP alone 
for 15, 30, or 60 min. Results shown are representative of three independent experiments. Values 
represent mean ± SEM. ***P<0.001; ****P <0.0001. (B) Representative images of Raw264.7 
cells incubated with 5M Hx-ZnMP, HSA-ZnMP or ZnMP alone for 30 min. 
 
 
Figure S2. Hx limits heme-induced ROS production in Raw 264.7 cells. Representative FACS 
analysis of H2DCFDA fluorescence in Raw264.7 cells untreated (NT) or treated with 15 μM Hx-
heme, HSA-heme or MSA-heme for 20 hours. Results shown are representative of three 
independent experiments. Values represent mean ± SEM. *P<0.05; **P<0.01; ***P<0.001. 
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Figure S3. Gating strategy and an example for heme-induced M1 polarization in BMDMs. 
(A) Gating strategy used to select BMDMs: after the selection of single live cells, the analysis of 
polarization markers was performed on the F4/80
+
 cells. (B) Representative flow cytometry 
analysis of the M2 marker CD206 in BMDM untreated (NT), treated with heme-bound to Hx or 
to BSA, as control. Heme-BSA induces a shift in the expression of CD206 that is rescued by the 
addition of the heme scavenger Hx. 
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Figure S4. Aged RBCs induce macrophage polarization towards a M1-like phenotype. 
BMDMs were left untreated (NT) or exposed to 2x10
7 
aged RBCs (+RBC) for 6 hours. M1 
markers are shown in the left column, M2 markers in the central column and iron genes in the 
right column of the panel. The expression of MHCII, CD86 and CD206 was analysed by flow 
cytometry and is expressed in Relative Fluorescence Units (RFU) as fold change compared to 
untreated cells (NT). The mRNA levels of Arginase1, TNF, Ym1, TfR1, HO-1 and Fpn were 
analysed by qRT-PCR and expressed in Relative Quantity (RQ), as fold change compared to 
untreated cells (NT). Results shown are the average of three independent experiments. Values 
represent mean ± SEM. **P<0.01; ***P<0.001; ****P <0.0001. 
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Figure S5. Heme induces the expression of pro-inflammatory cytokines. M0 BMDMs were 
left untreated (NT) or exposed to 5μM BSA-heme (+Heme) without (black bar) or with 400nM 
TAK-242, 2mM NAC or with 5M heme-Hx (grey bar) for 12 hours. The mRNA levels of IL-6, 
IL-1 and Ym1 were analysed by qRT-PCR and expressed in Relative Quantity (RQ), as fold 
change compared to untreated cells (NT). The expression of CD86 was analysed by flow 
cytometry and expressed in Relative Fluorescence Units (RFU) as fold change compared to M0 
untreated cells (NT). Results shown are the average of at least three independent experiments. 
Values represent mean ± SEM. *P<0.05; **P<0.01; ***P<0.001. 
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Figure S6. FeNTA induces macrophage polarization towards a M1-like phenotype, 
independently of the initial cell differentiation state. M0 (A), M1 (B) and M2 (C) BMDMs 
were left untreated (NT) or exposed to 100M FeNTA (+FeNTA) for 18 hours. M1 and M2 
markers are shown in the left and right column of each panel, respectively. The expression of 
MHCII, CD86, CD14 and CD206 was analysed by flow cytometry and is expressed in Relative 
Fluorescence Units (RFU) as fold change compared to untreated cells (NT). The mRNA levels of 
TNF, Arginase-1, Ym1 and IL-10 were analysed by qRT-PCR and expressed in Relative 
Quantity (RQ), as fold change compared to untreated cells (NT). Results shown are the average 
of at least three independent experiments. Values represent mean ± SEM. *P<0.05; **P<0.01; 
***P<0.001; ****P <0.0001. 
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Figure S7. Expression of M1 and M2 markers in M0, M1 and M2 BMDMs. M0, M1 and M2 
BMDMs were left untreated (NT) or exposed to 5μM BSA-heme (+Heme) for 12 hours (A) or 
100μM FeNTA (+FeNTA) for 18 hours (B). The expression of CD86 and CD206 was analysed 
by flow cytometry and expressed in Relative Fluorescence Units (RFU) as fold change compared 
to M0 untreated cells (black empty bar, NT). The mRNA levels of TNF and Arginase1 were 
analysed by qRT-PCR and expressed in Relative Quantity (RQ), as fold change compared to M0 
untreated cells (grey empty bar, NT). Results shown are the average of at least three independent 
experiments. Values represent mean ± SEM. *P<0.05; ***P<0.001; ****P <0.0001. 
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Figure S8. Protoporphyrin IX does not affect the expression of iron genes and polarization 
markers. M0, M1 and M2 BMDMs were left untreated (NT) or exposed to 5μM Protoporphyrin 
IX (+PPIX) or to 5μM BSA-heme (+Heme) for 12 hours. The mRNA levels of HO-1 and 
TNFwere analysed by qRT-PCR and expressed in Relative Quantity (RQ), as fold change 
compared to M0 untreated cells (NT). Values represent mean ± SEM. **P<0.01; ***P<0.001. 
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Figure S9. Expression of iron-related genes in M0, M1 and M2 BMDM untreated or treated 
with heme or iron. M0, M1 and M2 BMDMs were left untreated (NT) or exposed to 5μM BSA-
heme (+Heme) for 12 hours (A) or 100μM FeNTA (+FeNTA) for 18 hours (B). The mRNA 
levels of TfR1, HO-1 and Fpn were analysed by qRT-PCR and expressed in Relative Quantity 
(RQ), as fold change compared to M0 untreated cells (grey empty bar, NT). Results shown are 
the average of at least three independent experiments. Values represent mean ± SEM. *P<0.05; 
**P<0.01; ***P<0.001. 
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Figure S10. Gating strategy and example of heme-induced M1 polarization in ex vivo 
hepatic  macrophages. (A) Gating strategy used to select liver macrophages: after the selection 
of single live cells, the analysis of polarization markers was performed on the Gr1
-
 F4/80
+
 
CD11b
low
 liver cells. (B) Representative flow cytometry analysis of MHCII, CD86 and CD206 in 
macrophages isolated from the liver of mice challenged with Hx-heme or HSA-heme. HSA-heme 
induces a shift in the expression of polarization markers that is prevented in cells from animals 
challenged with Hx-heme. 
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Figure S11. Gating strategy and example of heme-induced M1 polarization in ex vivo 
splenic  macrophages. (A) Gating strategy used to select spleen macrophages: after the selection 
of single live cells, the analysis of polarization markers was performed on Gr1
-
 F4/80
+
 CD11b
low 
spleen cells. (B) Representative flow cytometry analysis of MHCII, CD86 and CD206 in 
macrophages isolated from the spleen of mice challenged with Hx-heme or HSA-heme. HSA-
heme induces a shift in the expression of polarization markers that is prevented in cells from 
animals challenged with Hx-heme. 
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Figure S12. TAK-242 and NAC do not affect the expression of polarization markers per se. 
M0 BMDMs  were left untreated (NT) or treated with 400nM TAK-242 or 2mM NAC for 12 
hours. The expression of CD206, CD14 and MHCII was analysed by flow cytometry and 
expressed in Relative Fluorescence Units (RFU) as fold change compared to untreated cells (NT). 
Values represent mean ± SEM. ***P<0.001; ****P<0.0001. 
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Figure S13. The anti-oxidant NAC rescue iron-induced M1 polarization of macrophages. 
M0 (A), M1 (B) and M2 (C) BMDMs were left untreated (NT) or exposed to 100M FeNTA 
(+FeNTA) with or without 2mM NAC for 18 hours. M1 and M2 markers are shown in the left 
and right column of each panel, respectively. The expression of MHCII, CD14 and CD206 was 
analysed by flow cytometry and expressed in RFU as fold change to untreated cells (NT). mRNA 
levels of TNF, Arginase-1 and IL-10 were analysed by qRT-PCR and expressed in RQ, as fold 
change to untreated cells (NT). Results shown are representative of three independent 
experiments. Values represent mean ± SEM. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. 
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Figure S14. Hx and DFO prevent M1 polarization of macrophages following hemolytic aged 
RBC treatment. M0 BMDMs were left untreated (NT) or exposed to 2x10
7 
aged  RBCs (+RBC) 
with or without 100M Hx or 100M DFO for 6 hours. M1 and M2 markers are shown in the left 
and right column of the panel, respectively. The expression of MHCII and CD206 was analysed 
by flow cytometry and expressed in RFU as fold change to untreated cells (NT). mRNA levels of 
TNF and Arginase1 were analysed by qRT-PCR and expressed in RQ, as fold change to 
untreated cells (NT). Results shown are representative of three independent experiments. Values 
represent mean ± SEM. *P<0.05; **P<0.01; ***P<0.001. 
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Figure S15. DFO prevent M1 polarization of macrophages in response to iron. M0 (A), M1 
(B) and M2 (C) BMDMs were left untreated (NT) or exposed to 100M FeNTA (+FeNTA), with 
or without 100M DFO for 18 hours. M1 and M2 markers are shown in the left and right column 
of each panel, respectively. The expression of MHCII, CD86 and CD206 was analysed by flow 
cytometry and expressed in RFU as fold change to untreated cells (NT). mRNA levels of TNF, 
Arginase-1 and IL-10 were analysed by qRT-PCR and expressed in RQ, as fold change to 
untreated cells (NT). Results shown are representative of three independent experiments. Values 
represent mean ± SEM. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. 
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Figure S16. Hx and DFO do not affect the expression of polarization markers per se. qRT- 
M0 BMDMs  were left untreated (NT) or treated with 100M DFO for 18 hours or 5M Hx for 
12 hours. The expression of CD86 and CD206 was analysed by flow cytometry and expressed in 
Relative Fluorescence Units (RFU) as fold change compared to untreated cells (NT). The mRNA 
levels of TNF and Arginase1 were analysed by qRT-PCR and expressed in Relative Quantity 
(RQ), as fold change compared to untreated cells (NT).Values represent mean ± SEM. **P<0.01; 
***P<0.001; ****P<0.0001. 
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Figure S17. Sickle mice show increased hepatic collagen deposition and parenchymal cell 
apoptosis. Picrosirius red staining for collagen (left panel), Tunel staining for apoptosis (central 
panel) and hematoxylin/eosin staining (right panel) on liver sections from control HbA and sickle 
HbS mice. Arrows indicate collagen (picrosirius), apoptotic cells (tunel), damaged areas and 
infiltrating cells (Heme/eo). 
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Figure S18. Increased leukocyte recruitment and liver damage in heme-treated Hx-null 
mice. Immunohistochemistry for CD18 (IHC, upper panel) and hematoxylin/eosin staining 
(Hem/Eo, bottom panels) was performed on sections of liver from heme-treated wild-type (left 
column) and Hx-null mice (right column) (heme treatment: 70 mol heme/kg body weight, 6 
hours). The IHC for CD18 reveals an increased number of CD18
+
 cells in heme-treated Hx-null 
compared to wild-type mice. Areas of necrosis/apoptosis (light violet areas, heme/eo staining) are 
almost exclusively visible in heme-treated Hx-null mice. 
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Table S1. Sequence of primers used for qRT-PCR. 
 
